File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.annonc.2021.04.008
- Scopus: eid_2-s2.0-85107901304
- PMID: 33894335
- WOS: WOS:000658413300010
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
Title | Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 |
---|---|
Authors | |
Keywords | chemotherapy nonsquamous non-small-cell lung cancer pembrolizumab |
Issue Date | 2021 |
Citation | Annals of Oncology, 2021, v. 32, n. 7, p. 881-895 How to Cite? |
Abstract | Background: In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) versus placebo plus pemetrexed–platinum. We report updated efficacy outcomes from the protocol-specified final analysis, including outcomes in patients who crossed over to pembrolizumab from pemetrexed–platinum and in patients who completed 35 cycles (∼2 years) of pembrolizumab. Patients and methods: Eligible patients were randomized 2 : 1 to receive pembrolizumab 200 mg (n = 410) or placebo (n = 206) every 3 weeks (for up to 35 cycles, ∼2 years) plus four cycles of pemetrexed (500 mg/m2) and investigators’ choice of cisplatin (75 mg/m2) or carboplatin (area under the curve 5 mg·min/ml) every 3 weeks, followed by pemetrexed until progression. Patients assigned to placebo plus pemetrexed–platinum could cross over to pembrolizumab upon progression if eligibility criteria were met. The primary endpoints were OS and PFS. Results: After a median follow-up of 31.0 months, pembrolizumab plus pemetrexed–platinum continued to improve OS [hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.46-0.69] and PFS (HR, 0.49; 95% CI, 0.41-0.59) over placebo plus pemetrexed–platinum regardless of programmed death-ligand 1 expression. Objective response rate (ORR) (48.3% versus 19.9%) and time to second/subsequent tumor progression on next-line treatment (PFS2; HR, 0.50; 95% CI, 0.41-0.61) were improved in patients who received pembrolizumab plus pemetrexed–platinum. Eighty-four patients (40.8%) from the placebo plus pemetrexed–platinum group crossed over to pembrolizumab on-study. Grade 3-5 adverse events occurred in 72.1% of patients receiving pembrolizumab plus pemetrexed–platinum and 66.8% of patients receiving placebo plus pemetrexed–platinum. Fifty-six patients completed 35 cycles (∼2 years) of pembrolizumab; ORR was 85.7% and 53 (94.6%) were alive at data cut-off. Conclusions: Pembrolizumab plus pemetrexed–platinum continued to show improved efficacy outcomes compared with placebo plus pemetrexed–platinum, with manageable toxicity. These findings support first-line pembrolizumab plus pemetrexed–platinum in patients with previously untreated metastatic nonsquamous NSCLC. |
Persistent Identifier | http://hdl.handle.net/10722/326506 |
ISSN | 2023 Impact Factor: 56.7 2023 SCImago Journal Rankings: 13.942 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rodríguez-Abreu, D. | - |
dc.contributor.author | Powell, S. F. | - |
dc.contributor.author | Hochmair, M. J. | - |
dc.contributor.author | Gadgeel, S. | - |
dc.contributor.author | Esteban, E. | - |
dc.contributor.author | Felip, E. | - |
dc.contributor.author | Speranza, G. | - |
dc.contributor.author | De Angelis, F. | - |
dc.contributor.author | Dómine, M. | - |
dc.contributor.author | Cheng, S. Y. | - |
dc.contributor.author | Bischoff, H. G. | - |
dc.contributor.author | Peled, N. | - |
dc.contributor.author | Reck, M. | - |
dc.contributor.author | Hui, R. | - |
dc.contributor.author | Garon, E. B. | - |
dc.contributor.author | Boyer, M. | - |
dc.contributor.author | Kurata, T. | - |
dc.contributor.author | Yang, J. | - |
dc.contributor.author | Pietanza, M. C. | - |
dc.contributor.author | Souza, F. | - |
dc.contributor.author | Garassino, M. C. | - |
dc.date.accessioned | 2023-03-10T02:19:46Z | - |
dc.date.available | 2023-03-10T02:19:46Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Annals of Oncology, 2021, v. 32, n. 7, p. 881-895 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | http://hdl.handle.net/10722/326506 | - |
dc.description.abstract | Background: In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) versus placebo plus pemetrexed–platinum. We report updated efficacy outcomes from the protocol-specified final analysis, including outcomes in patients who crossed over to pembrolizumab from pemetrexed–platinum and in patients who completed 35 cycles (∼2 years) of pembrolizumab. Patients and methods: Eligible patients were randomized 2 : 1 to receive pembrolizumab 200 mg (n = 410) or placebo (n = 206) every 3 weeks (for up to 35 cycles, ∼2 years) plus four cycles of pemetrexed (500 mg/m2) and investigators’ choice of cisplatin (75 mg/m2) or carboplatin (area under the curve 5 mg·min/ml) every 3 weeks, followed by pemetrexed until progression. Patients assigned to placebo plus pemetrexed–platinum could cross over to pembrolizumab upon progression if eligibility criteria were met. The primary endpoints were OS and PFS. Results: After a median follow-up of 31.0 months, pembrolizumab plus pemetrexed–platinum continued to improve OS [hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.46-0.69] and PFS (HR, 0.49; 95% CI, 0.41-0.59) over placebo plus pemetrexed–platinum regardless of programmed death-ligand 1 expression. Objective response rate (ORR) (48.3% versus 19.9%) and time to second/subsequent tumor progression on next-line treatment (PFS2; HR, 0.50; 95% CI, 0.41-0.61) were improved in patients who received pembrolizumab plus pemetrexed–platinum. Eighty-four patients (40.8%) from the placebo plus pemetrexed–platinum group crossed over to pembrolizumab on-study. Grade 3-5 adverse events occurred in 72.1% of patients receiving pembrolizumab plus pemetrexed–platinum and 66.8% of patients receiving placebo plus pemetrexed–platinum. Fifty-six patients completed 35 cycles (∼2 years) of pembrolizumab; ORR was 85.7% and 53 (94.6%) were alive at data cut-off. Conclusions: Pembrolizumab plus pemetrexed–platinum continued to show improved efficacy outcomes compared with placebo plus pemetrexed–platinum, with manageable toxicity. These findings support first-line pembrolizumab plus pemetrexed–platinum in patients with previously untreated metastatic nonsquamous NSCLC. | - |
dc.language | eng | - |
dc.relation.ispartof | Annals of Oncology | - |
dc.subject | chemotherapy | - |
dc.subject | nonsquamous non-small-cell lung cancer | - |
dc.subject | pembrolizumab | - |
dc.title | Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.annonc.2021.04.008 | - |
dc.identifier.pmid | 33894335 | - |
dc.identifier.scopus | eid_2-s2.0-85107901304 | - |
dc.identifier.volume | 32 | - |
dc.identifier.issue | 7 | - |
dc.identifier.spage | 881 | - |
dc.identifier.epage | 895 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.isi | WOS:000658413300010 | - |